NASDAQ$CLLS
Cellectis SA-ADR · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Cellectis reported a substantial increase in Q4 2024 revenue, reducing net loss and improving financial stability.
Cellectis achieved a remarkable revenue increase in Q4 2024, reaching $28.92 million compared to just $0.28 million in the prior year. The company significantly reduced its net loss to $17.13 million from $41.79 million in Q4 2023. Operating losses improved to $21.45 million, supported by a financial gain of $4.77 million. The company ended the quarter with $264 million in cash, ensuring a runway into mid-2027.
- Q4 2024 revenue surged to $28.92 million from $0.28 million in Q4 2023.
- Net loss improved significantly to $17.13 million from $41.79 million in Q4 2023.
- Operating loss decreased to $21.45 million, showing an improving financial position.
- Strong cash position of $264 million ensures operational funding into mid-2027.
Headline financials
Revenue & EPS history
Cellectis SA · Revenue · Quarterly
$28.9M
Forward guidance
Cellectis expects continued clinical advancements in 2025, with ongoing trials and expansion of its gene therapy pipeline.
Tailwinds
- UCART22 Phase 1 dataset and late-stage development strategy expected in Q3 2025.
- Strong partnership with AstraZeneca, advancing three cell and gene therapy programs.
- Cash position ensures funding through mid-2027, supporting long-term growth.
- Advancements in solid tumor therapies using SMART CAR T strategy.
- Expansion of TALEN-based gene editing tools for enhanced precision and efficacy.
Headwinds
- Continued operating losses despite improved revenue performance.
- Regulatory risks associated with upcoming clinical trials and approvals.
- Potential delays in the enrollment of UCART20x22 Phase 1 study in relapsed B-cell NHL.
- High research and development expenses impacting short-term profitability.
- Macroeconomic factors and industry competition may impact long-term growth.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-2.2%
Avg return
Earnings day
-2.0%
Avg return
5 days after
-0.4%
Avg return
30 days after
38%
16 / 42 earnings
Positive
+9.3%
Q1 2022
Best reaction
-16.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +2.7% | — | — | |
| Q2 2025 | -16.1% | -13.9% | -12.9% | |
| Q1 2025 | +2.4% | +0.0% | -9.5% | |
| Q4 2024 | -3.9% | +1.6% | +11.6% | |
| Q3 2024 | -1.1% | -1.7% | +5.0% | |
| Q2 2024 | +1.0% | +2.0% | +11.3% | |
| Q1 2024 | -3.5% | -3.9% | -34.0% | |
| Q3 2023 | -16.4% | -12.2% | +0.7% | |
| Q2 2023 | -3.6% | -3.6% | +4.7% | |
| Q1 2023 | +2.2% | -1.6% | +7.0% | |
| Q4 2022 | -3.9% | -4.5% | -4.2% | |
| Q3 2022 | -7.5% | -9.5% | -13.8% | |
| Q2 2022 | +4.2% | +0.6% | +2.1% | |
| Q1 2022 | +9.3% | +20.0% | -2.4% | |
| Q4 2021 | -14.9% | -11.6% | +16.9% | |
| Q3 2021 | -4.8% | -12.7% | -35.8% | |
| Q2 2021 | +7.1% | +5.3% | +14.3% | |
| Q1 2021 | -3.8% | -6.3% | -14.2% | |
| Q4 2020 | -9.7% | +7.5% | -2.0% | |
| Q3 2020 | +3.4% | +2.9% | +78.4% | |
| Q2 2020 | -2.0% | +1.4% | -5.6% | |
| Q1 2020 | +2.7% | +7.2% | +15.3% | |
| Q4 2019 | +0.3% | -22.8% | -46.9% | |
| Q3 2019 | +2.8% | +9.3% | +18.2% | |
| Q2 2019 | -1.8% | +0.8% | -5.4% | |
| Q1 2019 | -3.2% | -6.7% | -26.5% | |
| Q4 2018 | +3.7% | +7.0% | +9.0% | |
| Q3 2018 | -5.4% | -14.7% | -26.6% | |
| Q2 2018 | +0.0% | -1.2% | +2.0% | |
| Q1 2018 | -1.1% | -2.9% | +6.6% | |
| Q4 2017 | -7.1% | -1.2% | -11.2% | |
| Q3 2017 | -6.4% | -5.3% | +6.9% | |
| Q2 2017 | -2.3% | -1.9% | +36.0% | |
| Q1 2017 | +1.2% | +2.4% | +0.6% | |
| Q4 2016 | -4.1% | +2.5% | +6.7% | |
| Q3 2016 | -3.3% | +0.3% | -5.3% | |
| Q2 2016 | -3.0% | -5.2% | -13.0% | |
| Q1 2016 | -7.6% | — | — | |
| Q4 2015 | +2.5% | — | — | |
| Q3 2015 | -0.9% | — | — | |
| Q2 2015 | +0.9% | — | — | |
| Q1 2015 | -1.6% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q4 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro